# First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma

> **NCT03287310** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 50 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GSK3511294
- **DRUG:** Placebo
- **DRUG:** Salbutamol/albuterol

## Key facts

- **NCT ID:** NCT03287310
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-17
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03287310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03287310, "First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03287310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*